Elasmogen Ltd has announced the appointment of Jane Dancer as the Chair of the Board.
Jane joined Elasmogen as a non-executive director in April 2022 on the back of new investment from BGF, The Bank and Scottish Enterprise who joined existing investors, Deepbridge Capital (BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen – ELASMOGEN). Elasmogen is a biotech company based in Aberdeen, Scotland, developing a pipeline of novel targeting single domain biologics known as soloMERsTM for inflammatory disease and cancer.
Jane brings a wealth of experience in biotech having been Chief Business Officer at F-star, Vice President of Business Development at Cellzome, and Director of Business Development at Cambridge Antibody Technology. Jane holds an MA and Ph.D. in Natural Sciences from the University of Cambridge and an MBA from The Cambridge Judge Business School. She has an active role in advising companies on business development and strategy and is currently on the board of Spirea, PharmEnable, Macomics and NanoSyrinx.
“I am delighted that Jane has agreed to become the new Chair of Elasmogen” said Caroline Barelle, CEO. “Since joining Elasmogen, Jane has contributed hugely to the strategy of the company. Her extensive experience and network have been invaluable to us during this stage of growth and I look forward to working together to take our first products into the clinic.”
Jane said “It is a privilege to Chair Elasmogen at such an exciting time for the company. Since joining the board, I have been impressed by Caroline and her team who have established a rich pipeline of differentiated therapeutics thanks to the unique properties of their soloMER technology. I look forward to contributing to their future success.”